Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883433 | 0.98 | LMNA (0.50) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL10938684 | 0.97 | LMNA (0.53) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL10780206 | 0.97 | LMNA (0.53) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL5883668 | 0.97 | ALDH1A1 (0.51) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL493858 | 0.86 | TSHR (0.43) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL14323854 | 0.80 | PAOX (0.38) | ALDH1A1KMT2APRKCAMEN1 | |
| SCHEMBL14322624 | 0.77 | FAAH (0.35) | LMNAKMT2ARECQLMEN1USP2 | |
| SCHEMBL7153486 | 0.76 | LMNA (0.49) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL7153487 | 0.76 | LMNA (0.49) | LMNAALDH1A1TSHREPHX2KMT2A | |
| SCHEMBL10777080 | 0.75 | MAPT (0.47) | LMNATSHRKMT2ARECQLUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | LMNA 3674/4885ALDH1A1 923/4885TSHR 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.